|
Variables
|
Coefficient (95% CI)
|
p-value⊥
|
Adjusted R2
|
|---|
|
Clinical/demographic
|
|
Gender (male)
|
0.32 (0.03, 0.60)
|
0.030
|
0.178
|
|
Treatment response
|
−0.46 (−0.65, −0.27)
|
<0.001
|
0.178
|
|
HAQ
|
−0.73 (−0.97, −0.49)
|
<0.001
|
0.178
|
|
Pain (VAS)
|
−0.04 (−0.11, 0.03)
|
0.316
|
0.177
|
|
Fatigue (VAS)
|
−0.06 (−0.12, 0.01)
|
0.083
|
0.182
|
|
PGA
|
−0.01 (−0.08, 0.07)
|
0.733
|
0.182
|
|
PhGA
|
−0.01 (−0.11, 0.09)
|
0.607
|
0.175
|
|
SF-36
|
|
MCS
|
0.31 (0.19, 0.43)
|
<0.001
|
0.230
|
|
Vitality
|
0.16 (0.08, 0.24)
|
<0.001
|
0.210
|
|
Social function
|
0.08 (0.02, 0.15)
|
0.008
|
0.191
|
|
Mental health
|
0.21 (0.13, 0.28)
|
<0.001
|
0.235
|
|
Role emotional
|
0.07 (0.04, 0.10)
|
<0.001
|
0.218
|
|
IPQ-R
|
|
Illness coherence
|
0.07 (0.04, 0.10)
|
<0.001
|
0.215
|
|
Treatment control
|
0.09 (0.03, 0.14)
|
0.002
|
0.197
|
|
Personal control
|
0.05 (0.01, 0.09)
|
0.008
|
0.191
|
|
Emotional representations
|
−0.07 (−0.10, −0.05)
|
<0.001
|
0.261
|
|
Consequences
|
−0.07 (−0.10, −0.03)
|
<0.001
|
0.208
|
|
UCL
|
|
Passive reacting
|
−0.08 (−0.12, −0.04)
|
<0.001
|
0.186
|
|
Active tackling
|
0.03 (−0.01, 0.07)
|
0.090
|
0.182
|
|
RAQoL
|
−0.04 (−0.07, −0.02)
|
0.001
|
0.199
|
- Results were obtained from multivariate linear regression models predicting the total ASES score at week 104 by predictors that were significant in univariate analyses and adjusting for age, gender, treatment type and response, auto-antibody status, cumulative CRP, cumulative SJC28 and baseline HAQ and DAS28-CRP or its components. Treatment response was treated as an ordinal variable with lower values representing earlier and more persistent response
- ⊥Bonferroni correction for multiple comparisons was applied, setting the significance level at p < 0.003
- ASES Arthritis Self-Efficacy Scale, SF-36 Short-Form 36, MCS mental component score, IPQ-R Revised Illness Perception Questionnaire, UCL Utrecht Coping List
